JAK–STAT inhibition impairs K‐RAS‐driven lung adenocarcinoma progression

Oncogenic K‐RAS has been difficult to target and currently there is no K‐RAS‐based targeted therapy available for patients suffering from K‐RAS‐driven lung adenocarcinoma (AC). Alternatively, targeting K‐RAS‐downstream effectors, K‐RAS‐cooperating signaling pathways or cancer hallmarks, such as tumo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Cancer
Main Authors: Mohrherr, Julian, Haber, Marcel, Breitenecker, Kristina, Aigner, Petra, Moritsch, Stefan, Voronin, Viktor, Eferl, Robert, Moriggl, Richard, Stoiber, Dagmar, Győrffy, Balázs, Brcic, Luka, László, Viktória, Döme, Balázs, Moldvay, Judit, Dezső, Katalin, Bilban, Martin, Popper, Helmut, Moll, Herwig P., Casanova, Emilio
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6856680/
https://ncbi.nlm.nih.gov/pubmed/31407334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32624
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados